{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9"},{"groupId":"OG001","value":"6.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"308"}],"units":"Participants"}],"description":"MACE were defined as nonfatal myocardial infarction, nonfatal stroke, and death from any cause.","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From Week 5 Day 1 (Day 29) to Week 49 Day 1 (Day 337)","title":"Percentage of Participants Who Experienced Major Adverse Cardiovascular Events (MACE)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}